These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9327902)

  • 1. Aliphatic N-methylpropargylamines: monoamine oxidase-B inhibitors and antiapoptotic drugs.
    Boulton AA; Yu PH; Davis BA; Paterson IA; Li XM; Juorio AV; Durden DA; Dyck LE
    Adv Pharmacol; 1998; 42():308-11. PubMed ID: 9327902
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiapoptotic actions of monoamine oxidase B inhibitors.
    Paterson IA; Tatton WG
    Adv Pharmacol; 1998; 42():312-5. PubMed ID: 9327903
    [No Abstract]   [Full Text] [Related]  

  • 3. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.
    Fowler CJ; Oreland L; Callingham BA
    J Pharm Pharmacol; 1981 Jun; 33(6):341-7. PubMed ID: 6115003
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
    Jenner P
    Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
    [No Abstract]   [Full Text] [Related]  

  • 5. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibition.
    Schoepp DD; Azzaro AJ
    J Neurochem; 1981 Aug; 37(2):527-30. PubMed ID: 6790675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
    Mawhinney M; Cole D; Azzaro AJ
    J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
    Klegeris A; McGeer PL
    Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal and astroglial monoamine oxidase: pharmacological implications of specific MAO-B inhibitors.
    Yu PH; Davis BA; Boulton AA
    Prog Brain Res; 1992; 94():309-15. PubMed ID: 1287721
    [No Abstract]   [Full Text] [Related]  

  • 12. Substrate selectivity of type A and type B monoamine oxidase in rat brain.
    Kinemuchi H; Wakui Y; Kamijo K
    J Neurochem; 1980 Jul; 35(1):109-15. PubMed ID: 6778959
    [No Abstract]   [Full Text] [Related]  

  • 13. The rational design of suicide substrates of amine oxidases.
    Palfreyman MG; McDonald IA; Bey P; Danzin C; Zreika M; Lyles GA; Fozard JR
    Biochem Soc Trans; 1986 Apr; 14(2):410-3. PubMed ID: 3086155
    [No Abstract]   [Full Text] [Related]  

  • 14. Monoamine oxidase B inhibitor, selegiline, reduces
    Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P
    Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B.
    Sterling J; Veinberg A; Lerner D; Goldenberg W; Levy R; Youdim M; Finberg J
    J Neural Transm Suppl; 1998; 52():301-5. PubMed ID: 9564630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some observations upon a new inhibitor of monoamine oxidase in brain tissue.
    Johnston JP
    Biochem Pharmacol; 1968 Jul; 17(7):1285-97. PubMed ID: 5659776
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhancement of rat brain cytosolic monoamine oxidase activity by clorgyline. Comparison with (-)-deprenyl and MDL 72145.
    Azam M; Jain S; Baquer NZ
    Biochem Pharmacol; 1990 Nov; 40(10):2215-8. PubMed ID: 2123104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of inhibitors on monoamine oxidase activity in mouse brain.
    Hall TR; Figueroa HR; Yurgens PB
    Pharmacol Res Commun; 1982 May; 14(5):443-53. PubMed ID: 6810387
    [No Abstract]   [Full Text] [Related]  

  • 19. Further studies on the inhibition of monoamine oxidase by M & B 9302 (clorgyline). II. Comparison of M & B 9302 inhibition with that of iproniazid.
    Hall DW; Logan BW
    Biochem Pharmacol; 1969 Aug; 18(8):1955-9. PubMed ID: 5811628
    [No Abstract]   [Full Text] [Related]  

  • 20. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
    Waldmeier PC; Spooren WP; Hengerer B
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):526-37. PubMed ID: 11138845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.